Faslodex (fulvestrant) Receives FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib

15 November 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication for Faslodex (fulvestrant), expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news